Research
Hormonal
Gut peptides such as GLP-1 and PYY, along with vagal afferent signaling, play a critical role in homeostatic appetite suppression and satiety signaling.
Your gut produces hormones like GLP-1 and PYY when you eat, which signal your brain to stop eating. This is a natural biological process. Understanding this can help explain why certain foods or eating patterns might affect your satiety levels.
GoodSupportsHIGH confidence
Glucagon-like peptide-1 (GLP-1) is involved in decreasing appetite, inhibits gastric emptying, and is secreted in response to food consumption by the intestinal enteroendocrine L-cells... PYY lowers gastric mobility... and reducing appetite while inducing satiety.
Why this rating
Well-established mechanisms cited with multiple references.
Source
Neurobiology of eating behavior, nutrition, and health
Patrick J. Stover et al. · Journal of Internal Medicine · 2023
DOI 10.1111/joim.13699
narrative_reviewCited 75×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity is a neurobehavioral disorder resulting from the interaction of a 'vulnerable brain' (biological dysregulation of homeostatic and hedonic pathways) and an obesogenic food environment, rather than solely a failure of willpower.Good
- Eating rate is a primary driver of increased calorie intake, and slowing consumption through product reformulation represents a viable public health intervention to reduce energy intake.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →